{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:52:17Z","timestamp":1792756337285,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["69006662, 6905134, and 8601286"],"award-info":[{"award-number":["69006662, 6905134, and 8601286"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) have pleiotropic properties that may affect glomerular podocytes. We studied the effects of SGLT2i and HIF-PHI on cultured podocytes and human diabetic kidney disease (DKD) specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cultured human podocytes were treated with high glucose, Dapagliflozin, or Roxadustat. Podocyte-associated molecules levels and morphological changes were assessed. We then studied the kidney biopsy of 5 DKD patients treated with SGLT2i and 5 untreated DKD patients (control group). The distribution patterns of podocyte-associated molecules were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In high glucose condition, cultured podocytes had reduced mRNA expression of nephrin, podocalyxin, and synaptopodin, which was restored by treatment with Dapagliflozin, Roxadustat, or both. The corresponding intracellular protein levels were similarly reduced in high glucose and partly restored by Dapagliflozin, Roxadustat, or both. In high glucose condition, podocyte cell bodies were shrunken, and the distribution of nephrin and podocin on cell surface became granular, which were restored to the normal linear pattern when treated with Dapagliflozin, Roxadustat, or both. In high glucose condition, podocalyxin distribution at podocyte apical membrane was disorganized, while the expression of synaptopodin was reduced in the cell processes, with the punctate appearance disrupted; Dapagliflozin, but not Roxadustat, partly restored their normal distribution. In human DKD, the disorganized nephrin, podocin, podocalyxin, and synaptopodin distribution was similar to cultured podocytes, and the disrupted distribution returned to the normal linear continuous pattern with SGLT2i treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i Dapagliflozin and HIF-PHI Roxadustat partly restore the podocyte morphology and intracellular mRNA and protein levels of podocyte-associated molecule in a diabetic milieu.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04677-0","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T14:05:55Z","timestamp":1765029955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes"],"prefix":"10.1186","volume":"27","author":[{"given":"Chuanlei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack K. C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C. K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston W. S.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ming","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk-Chun","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"4677_CR1","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Cooper ME, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.","journal-title":"Nat Rev Dis Primers"},{"key":"4677_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molmet.2019.10.005","volume":"30","author":"H Fu","year":"2019","unstructured":"Fu H, Zhou D, et al. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metab. 2019;30:250\u201363.","journal-title":"Mol Metab"},{"key":"4677_CR3","unstructured":"Saran R, Shahinian V, et al. Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3 Suppl 1):A7\u20138. US Renal Data System 2018 Annual Data Report:."},{"issue":"7","key":"4677_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/CS20210625","volume":"136","author":"F Barutta","year":"2022","unstructured":"Barutta F, Bellini S, Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy. Clin Sci (Lond). 2022;136(7):493\u2013520.","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"4677_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1681\/ASN.2012040390","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23(12):1917\u201328.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4677_CR6","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.2337\/dc11-2189","volume":"35","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35(10):2061\u20138.","journal-title":"Diabetes Care"},{"issue":"4","key":"4677_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"7","key":"4677_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"4677_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJ Heerspink","year":"2017","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28(1):368\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4677_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.23876\/j.krcp.24.144","volume":"44","author":"B Jiang","year":"2025","unstructured":"Jiang B, Cheng Z, Wang D, Liu F, Wang J, Fu H, Mao J. Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors. Kidney Res Clin Pract. 2025;44(1):69\u201378.","journal-title":"Kidney Res Clin Pract"},{"issue":"15","key":"4677_CR11","doi-asserted-by":"publisher","first-page":"e98720","DOI":"10.1172\/jci.insight.98720","volume":"3","author":"P Cassis","year":"2018","unstructured":"Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, Morigi M, Remuzzi G, Benigni A, Zoja C. SGLT2 inhibitor Dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018;3(15):e98720.","journal-title":"JCI Insight"},{"issue":"1","key":"4677_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","volume":"22","author":"CJ Bailey","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22(1):39\u201352.","journal-title":"Curr Diab Rep"},{"issue":"11","key":"4677_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat treatment for anemia in patients undergoing Long-Term Dialysis. N Engl J Med. 2019;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"4677_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat for anemia in patients with kidney disease not receiving Dialysis. N Engl J Med. 2019;381(11):1001\u201310.","journal-title":"N Engl J Med"},{"issue":"5","key":"4677_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.kint.2019.12.007","volume":"97","author":"S Hasegawa","year":"2020","unstructured":"Hasegawa S, Nangaku M, et al. The oral hypoxia-inducible factor Prolyl hydroxylase inhibitor Enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int. 2020;97(5):934\u201350.","journal-title":"Kidney Int"},{"issue":"3","key":"4677_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1681\/ASN.2019060582","volume":"31","author":"M Sugahara","year":"2020","unstructured":"Sugahara M, Tanaka S, Tanaka T, Saito H, Ishimoto Y, Wakashima T, Ueda M, Fukui K, Shimizu A, Inagi R, Yamauchi T, Kadowaki T, Nangaku M. Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J Am Soc Nephrol. 2020;31(3):560\u201377.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"4677_CR17","first-page":"e63852","volume":"16","author":"M Basheeruddin","year":"2024","unstructured":"Basheeruddin M, Qausain S. Hypoxia-Inducible factor 1-Alpha (HIF-1\u03b1): an essential regulator in cellular metabolic control. Cureus. 2024;16(7):e63852.","journal-title":"Cureus"},{"issue":"1","key":"4677_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/hematolrep15010019","volume":"15","author":"S Yamasaki","year":"2023","unstructured":"Yamasaki S, Horiuchi T. Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose cotransporter 2 inhibitors for Low-Risk myelodysplastic Syndrome-Related anemia in patients with chronic kidney disease: A report of three cases. Hematol Rep. 2023;15(1):180\u20137.","journal-title":"Hematol Rep"},{"issue":"3","key":"4677_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1681\/ASN.V133630","volume":"13","author":"MA Saleem","year":"2002","unstructured":"Saleem MA, O\u2019Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and Podocin expression. J Am Soc Nephrol. 2002;13(3):630\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4677_CR20","doi-asserted-by":"publisher","first-page":"16617","DOI":"10.1038\/s41598-019-53214-1","volume":"9","author":"PZ Wei","year":"2019","unstructured":"Wei PZ, Fung WW, Ng JK, Lai KB, Luk CC, Chow KM, Li PK, Szeto CC. Metabolomic changes of human proximal tubular cell line in high glucose environment. Sci Rep. 2019;9(1):16617.","journal-title":"Sci Rep"},{"issue":"2","key":"4677_CR21","doi-asserted-by":"publisher","first-page":"e0247234","DOI":"10.1371\/journal.pone.0247234","volume":"16","author":"N Zaibi","year":"2021","unstructured":"Zaibi N, Li P, Xu SZ. Protective effects of Dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells. PLoS ONE. 2021;16(2):e0247234.","journal-title":"PLoS ONE"},{"key":"4677_CR22","doi-asserted-by":"publisher","first-page":"1503477","DOI":"10.3389\/fcell.2025.1503477","volume":"13","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Yang Q, Feng B, Yang X, Jin H. Roxadustat regulates the cell cycle and inhibits proliferation of mesangial cells via the hypoxia-inducible factor-1\u03b1\/P53\/P21 pathway. Front Cell Dev Biol. 2025;13:1503477.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4677_CR23","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1096\/fj.11-202994","volume":"26","author":"A Mima","year":"2012","unstructured":"Mima A, Kitada M, Geraldes P, Li Q, Matsumoto M, Mizutani K, Qi W, Li C, Leitges M, Rask-Madsen C, King GL. Glomerular VEGF resistance induced by PKC\u03b4\/SHP-1 activation and contribution to diabetic nephropathy. FASEB J. 2012;26(7):2963\u201374.","journal-title":"FASEB J"},{"issue":"9","key":"4677_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. CKD-EPI (Chronic kidney disease epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"4677_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-62703-453-1_17","volume":"1024","author":"G Wang","year":"2013","unstructured":"Wang G, Szeto CC. Methods of MicroRNA quantification in urinary sediment. Methods Mol Biol. 2013;1024:211\u201320.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"4677_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/dmrr.2654","volume":"31","author":"G Wang","year":"2015","unstructured":"Wang G, Lai FM, Chow KM, Kwan BC, Pang WF, Luk CC, Leung CB, Li PK, Szeto CC. Urinary mRNA levels of ELR-negative CXC chemokine ligand and extracellular matrix in diabetic nephropathy. Diabetes Metab Res Rev. 2015;31(7):699\u2013706.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"4677_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/ajh.2008.360","volume":"22","author":"G Wang","year":"2009","unstructured":"Wang G, Lai FM, Kwan BC, Lai KB, Chow KM, Li PK, Szeto CC. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens. 2009;22(3):300\u20136.","journal-title":"Am J Hypertens"},{"key":"4677_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO. 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"8","key":"4677_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0895-7061(03)00864-1","volume":"16","author":"AN Lasaridis","year":"2003","unstructured":"Lasaridis AN, Sarafidis PA. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? Am J Hypertens. 2003;16(8):689\u201397.","journal-title":"Am J Hypertens"},{"issue":"10365","key":"4677_CR30","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"15","key":"4677_CR31","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Wheeler DC, et al. DAPA-CKD trial committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"4677_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Haynes R, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"key":"4677_CR33","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","volume":"14","author":"ZC Dai","year":"2023","unstructured":"Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol. 2023;14:1213473.","journal-title":"Front Immunol"},{"issue":"7","key":"4677_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","volume":"32","author":"A Mima","year":"2018","unstructured":"Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications. 2018;32(7):720\u20135.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"4677_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/HYPERTENSIONAHA.113.01425","volume":"62","author":"M Friederich-Persson","year":"2013","unstructured":"Friederich-Persson M, et al. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension. 2013;62(5):914\u20139.","journal-title":"Hypertension"},{"issue":"3","key":"4677_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.ackd.2014.03.011","volume":"21","author":"FC Brosius","year":"2014","unstructured":"Brosius FC, Coward RJ. Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):304\u201310.","journal-title":"Adv Chronic Kidney Dis"},{"key":"4677_CR37","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1002\/jcp.30316","volume":"236","author":"K Jaikumkao","year":"2021","unstructured":"Jaikumkao K, Lungkaphin A, et al. Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK\/mTOR signaling pathway in obese rats. J Cell Physiol. 2021;236:6424\u201340.","journal-title":"J Cell Physiol"},{"key":"4677_CR38","doi-asserted-by":"publisher","first-page":"e22978","DOI":"10.1002\/jbt.22978","volume":"36","author":"L Thongnak","year":"2022","unstructured":"Thongnak L, Lungkaphin A, et al. The combination of Dapagliflozin and Statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats. J Biochem Mol Toxicol. 2022;36:e22978.","journal-title":"J Biochem Mol Toxicol"},{"key":"4677_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","volume":"29","author":"L Thongnak","year":"2021","unstructured":"Thongnak L, Lungkaphin A, et al. Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology. 2021;29:269\u201379.","journal-title":"Inflammopharmacology"},{"key":"4677_CR40","doi-asserted-by":"publisher","first-page":"14659","DOI":"10.1038\/s41598-020-71599-2","volume":"10","author":"R Hasan","year":"2020","unstructured":"Hasan R, Alam MA, et al. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model. Sci Rep. 2020;10:14659.","journal-title":"Sci Rep"},{"key":"4677_CR41","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.3390\/ijms21082987","volume":"21","author":"AI Korbut","year":"2020","unstructured":"Korbut AI, Bgatova NP, et al. SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db\/db mice, a model of type 2 diabetes. Int J Mol Sci. 2020;21:2987.","journal-title":"Int J Mol Sci"},{"key":"4677_CR42","doi-asserted-by":"publisher","first-page":"110206","DOI":"10.1016\/j.cellsig.2021.110206","volume":"90","author":"L Yang","year":"2022","unstructured":"Yang L, Li J, et al. Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK\/mTOR mediated autophagy pathway. Cell Signal. 2022;90:110206.","journal-title":"Cell Signal"},{"key":"4677_CR43","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ndt\/gfab330","volume":"37","author":"KL Hudkins","year":"2022","unstructured":"Hudkins KL, Li X, Holland AL, Swaminathan S, Alpers CE, et al. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob\/ob mice. Nephrol Dial Transpl. 2022;37:847\u201359.","journal-title":"Nephrol Dial Transpl"},{"key":"4677_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/ijms19010137","volume":"19","author":"D Wang","year":"2018","unstructured":"Wang D, Wang X, et al. The sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents renal and liver disease in Western diet induced obesity mice. Int J Mol Sci. 2018;19:137.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4677_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1523-1755.2004.00910.x","volume":"66","author":"K Datta","year":"2004","unstructured":"Datta K, Li J, Karumanchi SA, Wang E, Rondeau E, Mukhopadhyay D. Regulation of vascular permeability factor\/vascular endothelial growth factor (VPF\/VEGF-A) expression in podocytes. Kidney Int. 2004;66(4):1471\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"4677_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1203\/PDR.0b013e31821bdf1c","volume":"70","author":"J Ma","year":"2011","unstructured":"Ma J, Matsusaka T, Yang HC, Zhong J, Takagi N, Fogo AB, Kon V, Ichikawa I. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res. 2011;70(1):83\u20139.","journal-title":"Pediatr Res"},{"key":"4677_CR47","doi-asserted-by":"publisher","first-page":"174583","DOI":"10.1016\/j.ejphar.2021.174583","volume":"912","author":"A Mima","year":"2021","unstructured":"Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021;912:174583.","journal-title":"Eur J Pharmacol"},{"key":"4677_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bbrc.2022.02.091","volume":"602","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Zhang YL, et al. Hypoxia-inducible factor-1\u03b1 activation can attenuate renal podocyte injury and alleviate proteinuria in rats in a simulated high-altitude environment. Biochem Biophys Res Commun. 2022;602:35\u201340.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04677-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04677-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04677-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:15:21Z","timestamp":1768342521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04677-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4677"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04677-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee (approval numbers CRE-2024.551). All study procedures were in compliance with the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}